機構股票研究
機構股票研究
機構股票研究
機構股票研究 
 
Page | 1 | PHILLISECURITIES (HK) RESEARCH 
恒瑞醫藥
恒瑞醫藥
恒瑞醫藥
恒瑞醫藥(600276.CH) 
阿帕替尼新進國家醫保 
 
中國
中國
中國
中國 | 醫藥
醫藥
醫藥
醫藥| 公司研報
公司研報
公司研報
公司研報 
 
 
 
2 August 2017 
 
投資總結
投資總結
投資總結
投資總結 
 
恒瑞醫藥在國內醫藥行業中居於龍頭地位，目前有多個重磅品種待批，未來將面
臨創新藥次第獲批、製劑出口加速及仿製藥集中度提升等多重利好，業績持續約20%
的增速。給予其對應2017 年EPS 50 倍估值，目標價為56.5 元，為“增持”評級。(現
價截至7 月31 日) 
 
Historical Valuation of Hengrui Medicine 
 
Source: Bloomberg, Phillip Securities (HK) Research 
 
阿帕替尼新進國家醫保
阿帕替尼新進國家醫保
阿帕替尼新進國家醫保
阿帕替尼新進國家醫保 
 
根據談判，公司主要產品阿帕替尼納入國家醫保乙類，支付標準相比原售價平均
下降37%，但降幅明顯小於進口靶向抗腫瘤藥物。目前全球獲批胃癌靶向藥物僅三
種，因胃癌對個體化治療要求較高，因此已上市藥物市場優勢明顯。 
 
自2014 年底獲批以來，阿帕替尼銷售額高速增長，2016 年即已達至8.5 億元規
模。除胃癌外，公司還在拓展該品種的適應症，包括肝癌、肺癌、乳腺癌等，將進一
步拓展市場空間。此次新進醫保亦有助於其銷量釋放，其於胃癌市場滲透率有望從目
前不足10%升至30%以上。未來獲批新適應症後，銷售額更有望達至二三十億元。 
 
製劑出口高速成長可期
製劑出口高速成長可期
製劑出口高速成長可期
製劑出口高速成長可期 
 
公司近日分別收到英國、德國、荷蘭藥監局通知，批准公司吸入地氟烷在各國的
上市申請。地氟烷目前除了原研外，沒有仿製藥獲批上市，競爭格局良好，因此將有
望快速佔領市場，成為又一個繼環磷醯胺式的高毛率品種。而且，因為利用同一生產
線，該品種還成功進入第21 批優先審評名單，將加速國內上市步伐，進而補充公司麻
醉產品線。 
 
2017 年以來，公司在美國上市品種新增阿曲庫銨、多西他賽，獲批總數達至8
個，在歐洲市場則已獲批卡泊芬淨、七氟烷。總體上，公司製劑出口產品線不斷擴
充，獲批速度加快，未來兩年還有5-8 個品種有望獲批，並不排除類似環磷醯胺的重
磅品種獲批，這將明顯提升公司競爭力，帶動國際業務迎來30％以上增速的高增長
期。 
增持
增持
增持
增持 (下調
下調
下調
下調) 
現價: CNY 51.20 
(現價截至7 月31 日) 
目標價: CNY 56.50 (+10.4%) 
 
公司資料
公司資料
公司資料
公司資料 
普通股股東 (百萬股) : 
2,817
市值 (人民幣百萬元) : 
144,225
52 周 最高價/最低價 (人民幣元) :
60.40/ 42.50
 
 
 
 
主要股東
主要股東
主要股東
主要股東， % 
江蘇恒瑞醫藥集團: 
24.31
 
 
 
股價表現
股價表現
股價表現
股價表現， % 
1 個月
個月
個月
個月
3 個月
個月
個月
個月
1 年
恒瑞醫藥 
1.58
-5.11
16.19
上證指數 
-0.95
-8.23
7.54
 
股價
股價
股價
股價 & 上證指數
上證指數
上證指數
上證指數 
 
Source: Phillip Securities (HK) Research 
 
財務資料
財務資料
財務資料
財務資料 
CNY mn 
FY15
FY16
FY17E
FY18E
Net Sales 
9316 10891 13137 15703
Net Profit 
2172
2589
3181
3808
EPS, CNY 
1.12
0.92
1.13
1.35
PER, x 
45.9
55.7
45.3
37.8
BVPS, CNY 
5.09
5.27
5.59
6.81
P/BV, x 
10.1
9.7
9.2
7.5
ROE, %  
24.5
23.2
22.2
21.8
Debt/Equity (%)
11.0
11.3
11.1
11.1
Source: Company reports, Phillip Securities Est. 
 
研究分析員 
範國和
範國和
範國和
範國和  
(+ 86 21 51699400-110) 
fanguohe@phillip.com.cn 
 
 
 
 
Page | 2 | PHILLISECURITIES (HK) RESEARCH 
恒瑞醫藥
恒瑞醫藥
恒瑞醫藥
恒瑞醫藥（600276 CH）公司研報
公司研報
公司研報
公司研報 
 
強大研發支撐產品線拓展
強大研發支撐產品線拓展
強大研發支撐產品線拓展
強大研發支撐產品線拓展 
 
公司是國內領先的研髮型醫藥企業，研發費用占比在全行業佔據首位，目
前研發產品線以抗腫瘤為核心，涵蓋糖尿病、心血管等重大疾病，創新藥梯隊
有逾20 個產品，未來有望每年1-2 個新藥上市，法米替尼、長效粒細胞集落刺
激因數、吡咯替尼等創新藥梯隊有望於2018-2019 年陸續上市。 
 
% of R&D of Hengrui Medicine 
 
Source: Company reports, Phillip Securities (HK) Research 
 
還值一提的是，目前國內醫藥政策包括仿製藥一致性評價、優先審評等將
驅升處方藥進入強者恒強時代。恒瑞無論是研發還是銷售能力均處於行業龍頭
地位，產品線日趨豐富，再加上產業集中度提升等因素，公司經營業績將維持
高速增長。 
 
風險
風險
風險
風險 
 
傳統仿製品降價超預期； 
在研品種審批進展低於預期。 
 
 
 
 
 
 
 
 
 
 
Page | 3 | PHILLISECURITIES (HK) RESEARCH 
恒瑞醫藥
恒瑞醫藥
恒瑞醫藥
恒瑞醫藥（600276 CH）公司研報
公司研報
公司研報
公司研報 
 
財務報告
財務報告
財務報告
財務報告 
 
FYE
2014
2015
2016
2017F
2018F
Valuation Ratios
Price Earnings
65.9x
45.9x
55.7x
45.3x
37.8x
Price to Book
12.8x
10.1x
9.7x
9.2x
7.5x
Dividend Yield
0.2%
0.2%
0.2%
0.3%
0.3%
Per share data(RMB))
EPS Adjusted
0.78
1.12
0.92
1.13
1.35
Book Value Per Share
4.01
5.09
5.27
5.59
6.81
Dividends Per Share
0.08
0.10
0.11
0.14
0.15
Growth& Margin
Revenue growth
22.2%
25.0%
16.9%
20.6%
19.5%
Gross Profit growth
21.6%
29.7%
21.4%
20.9%
19.8%
Net Profit growth
22.4%
43.3%
19.2%
22.9%
19.7%
Profitability Ratios
Gross Margin
80.6%
83.6%
86.8%
87.0%
87.2%
Net Profit Margin
20.3%
23.3%
23.8%
24.2%
24.3%
Dividend Payout Ratio %
9.9%
9.0%
12.2%
12.4%
11.1%
Key Ratios
Return on Assets
18.6%
21.1%
20.0%
20.0%
19.6%
Return on Equity
21.4%
24.5%
23.2%
22.2%
21.8%
Effective Tax Rate
12.6%
13.2%
12.6%
12.8%
12.8%
Liability ratio
10.3%
9.9%
10.2%
10.0%
10.0%
Income Statement(RMB: mn)
Revenue
7,452
9,316
10,891
13,137
15,703
     - Cost of Goods Sold
1,313
1,372
1,435
1,708
2,010
Gross Income
6,006
7,789
9,456
11,429
13,693
    - Selling, General & Admin Expe
4,315
5,376
6,613
7,882
9,422
Operating Income
1,692
2,413
2,844
3,547
4,271
    - Net Non-Operating Losses (Ga
-108
-126
-128
-145
-155
Pretax Income
1,800
2,562
3,013
3,722
4,456
     - Income Tax Expense
227
338
379
476
570
Income Before XO Items
1,573
2,224
2,634
3,246
3,886
     - Minority Interests
57
52
45
65
78
Net Profit
1,516
2,172
2,589
3,181
3,808
Source: Company, Phillip Securities (HK) Research Estimates 
(財務資料截至7 月31 日) 
  
 
 
 
 
 
 
 
 
 
 
 
PHILL
 
恒瑞醫藥
恒瑞醫藥
恒瑞醫藥
恒瑞醫藥（600276 CH）公司研報
公司研報
公司研報
公司研報 
PHILLIP RESEARCH STOCK SELECTION SYSTEMS 
 
We do not base our recommendations entirely on the above quantitative return bands.  We consider qualitative factors like (but not limited to) a 
stock's risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative 
undertones surrounding the stock, before making our final recommendation 
 
GENERAL DISCLAIMER 
This publication is prepared by Phillip Securities (Hong Kong) Ltd (“Phillip Securities”). By receiving or reading this publication, you agree to be bound by the terms and 
limitations set out below. 
 
This publication shall not be reproduced in whole or in part, distributed or published by you for any purpose. Phillip Securities shall not be liable for any direct or 
consequential loss arising from any use of material contained in this publication. 
 
The information contained in this publication has been obtained from public sources which Phillip Securities has no reason to believe are unreliable and any analysis, 
forecasts, projections, expectations and opinions (collectively the “Research”) contained in this publication are based on such information and are expressions of belief 
only. Phillip Securities has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, 
complete or verified or should be relied upon as such. Any such information or Research contained in this publication is subject to change, and Phillip Securities shall not 
have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will 
Phillip Securities be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made 
available, even if it has been advised of the possibility of such damages. 
 
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this material are as of the date indicated and are subject to change at any time 
without prior notice. 
 
This material is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any 
particular person. The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a 
financial adviser regarding the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, 
before making a commitment to invest in any of such products. 
This publication should not be relied upon as authoritative without further being subject to the recipient’s own independent verification and exercise of judgment. The 
fact that this publication has been made available constitutes neither a recommendation to enter into a particular transaction nor a representation that any product 
described in this material is suitable or appropriate for the recipient. Recipients should be aware that many of the products which may be described in this publication 
involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made unless all 
such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein 
with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks. 
 
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in this research 
should take into account existing public information, including any registered prospectus in respect of such security. 
 
Disclosure of Interest 
Analyst Disclosure: Neither the analyst(s) preparing this report nor his associate has any financial interest in or serves as an officer of the listed corporation covered in 
this report. 
Firm’s Disclosure: Phillip Securities does not have any investment banking relationship with the listed corporation covered in this report nor any financial interest of 1% or 
more of the market capitalization in the listed corporation. In addition, no executive staff of Phillip Securities serves as an officer of the listed corporation. 
 
Availability 
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where 
such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities to any registration or 
licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction. 
 
Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited (“PSHK”) believed to be accurate. PSHK does not bear responsibility for any 
loss occasioned by reliance placed upon the contents hereof.  PSHK (or its affiliates or employees) may have positions in relevant investment products. For details of 
different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk.   
© 
2017 Phillip Securities (Hong Kong) Limited 
 
Contact Information (Regional Member Companies) 
Total Return 
Recommendation 
Rating 
Remarks 
>+20% 
Buy 
1 
>20% upside from the current price 
+5% to +20% 
Accumulate 
2 
+5% to +20%upside from the current price 
-5% to +5% 
Neutral 
3 
Trade within  ± 5% from the current price 
-5% to -20% 
Reduce 
4 
-5% to -20% downside from the current price 
<-20% 
Sell 
5 
>20%downside from the current price 
 
 
 
PHILL
 
恒瑞醫藥
恒瑞醫藥
恒瑞醫藥
恒瑞醫藥（600276 CH）公司研報
公司研報
公司研報
公司研報 
SINGAPORE 
Phillip Securities Pte Ltd 
Raffles City Tower 
250, North Bridge Road #06-00 
Singapore 179101 
Tel : (65) 6533 6001 
Fax : (65) 6535 6631 
Website: www.poems.com.sg 
MALAYSIA 
Phillip Capital Management Sdn Bhd 
B-3-6 Block B Level 3 Megan Avenue II, 
No. 12, Jalan Yap Kwan Seng, 50450 
Kuala Lumpur 
Tel (603) 21628841 
Fax (603) 21665099 
Website: www.poems.com.my 
 
HONG KONG 
Phillip Securities (HK) Ltd 
Exchange Participant of the Stock Exchange of Hong Kong 
11/F United Centre 95 Queensway 
Hong Kong 
Tel (852) 22776600 
Fax (852) 28685307 
Websites: www.phillip.com.hk 
 
JAPAN 
PhillipCapital Japan K.K. 
Nagata-cho Bldg., 
8F, 2-4-3 Nagata-cho, 
Chiyoda-ku, Tokyo 100-0014 
Tel (81-3) 35953631 
Fax (81-3) 35953630 
Website:www.phillip.co.jp 
 
INDONESIA 
PT Phillip Securities Indonesia 
ANZ Tower Level 23B, 
Jl Jend Sudirman Kav 33A 
Jakarta 10220 – Indonesia 
Tel (62-21) 57900800 
Fax (62-21) 57900809 
Website:www.phillip.co.id 
 
CHINA 
Phillip Financial Advisory (Shanghai) Co. Ltd 
No 436 Hengfeng Road, 
Greentech Unit 604, 
Postal code 200070 
Tel (86-21) 51699400 
Fax (86-21) 63532643 
Website: www.phillip.com.cn 
 
THAILAND 
Phillip Securities (Thailand) Public Co. Ltd 
15th Floor, Vorawat Building, 
849 Silom Road, Silom, Bangrak, 
Bangkok 10500 Thailand 
Tel (66-2) 6351700 / 22680999 
Fax (66-2) 22680921 
Websitewww.phillip.co.th 
 
FRANCE 
King & Shaxson Capital Limited 
3rd Floor, 35 Rue de la Bienfaisance 75008 
Paris France 
Tel (33-1) 45633100 
Fax (33-1) 45636017 
Website: www.kingandshaxson.com 
 
UNITED KINGDOM 
King & Shaxson Capital Limited 
6th Floor, Candlewick House, 
120 Cannon Street, 
London, EC4N 6AS 
Tel (44-20) 7426 5950 
Fax (44-20) 7626 1757 
Website: www.kingandshaxson.com 
 
UNITED STATES 
Phillip Futures Inc 
141 W Jackson Blvd Ste 3050 
The Chicago Board of Trade Building 
Chicago, IL 60604 USA 
Tel +1.312.356.9000 
Fax +1.312.356.9005 
 
AUSTRALIA 
PhillipCapital Australia 
Level 12, 15 William Street, 
Melbourne, Victoria 3000, Australia 
Tel (613) 96188238 
Fax (613) 92002272 
Website: www.phillipcapital.com.au 
 
 
